Celgene licenses GlobeImmune’s thyroid cancer drug

Posted: August 13th, 2015  |  Company/topic: Celgene
Celgene has licensed GlobeImmune's thyroid cancer drug GI-6207 as part of a licensing pact between the firms.  -More- …

Patent challenger Bass shrugs off Celgene’s attack on his short-selling motives

Posted: August 12th, 2015  |  Company/topic: Celgene
Money makes the world go round--the patent world, that is. That's the word from hedge funder Kyle Bass, who has been targeting drug patents he calls "low quality," and shorting pharma stocks along the…

Celgene buys into GlobeImmune’s cancer immunotherapy

Posted: August 5th, 2015  |  Company/topic: Celgene
GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy.

UPDATE – Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy

Posted: August 4th, 2015  |  Company/topic: Celgene
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to e…